egg-rcts-diabetic-metabolic

Orientation — slice 6: egg RCTs in diabetic/prediabetic/metabolic-syndrome populations

Interventional (randomised/controlled feeding) evidence testing whether eggs affect cardiometabolic outcomes (glycemic control, lipids, blood pressure, inflammation, endothelial function) specifically in clinically-defined populations — T2D, prediabetes, metabolic syndrome. This is the interventional counterpart to slice 3’s observational “eggs and diabetes” signal.

Sources by topic (best-first within each group)

The DIABEGG trials — the core “high egg intake is safe in T2D” anchor

1. S-26 - DIABEGG 3-month RCT — high-egg vs low-egg diet in prediabetes-T2D (Fuller 2015).md — foundational 3-month phase, 140 randomized, no adverse lipid/glycemic effect, most-cited (103) source in the slice.
2. S-31 - DIABEGG weight-loss and 12-month follow-up phase in T2D (Fuller 2018).md — same cohort (128) carried to 12 months through an active weight-loss phase, still null; shares its data basis with S-26, not independent of it.

Other whole-/moderate-egg RCTs directly in T2D or prediabetes — null-to-beneficial 3. S-37 - Energy-restricted high-protein diet with eggs vs lean meat in T2D-IGT (Pearce 2011).md — T2D/IGT weight-loss RCT, explicit disclosed egg-industry (Australian Egg Corporation) funding, favorable lipid/glycemic results. 4. S-34 - One egg-day vs oatmeal breakfast crossover trial in T2D (Ballesteros 2015).md — Mexican group, independent of the Australian/US cluster, favorable inflammatory signal, null lipid/glycemic. 5. S-46 - One egg-day vs egg substitute in pre—type-2-diabetes, glycemic outcomes (Pourafshar 2018).md — independent US group, improved fasting glucose/HOMA-IR with 1 egg/day.

Metabolic-syndrome-defined whole-egg RCTs (same lab, two trials) 6. S-43 - Whole egg vs egg substitute in carbohydrate-restricted diet, metabolic syndrome (Blesso 2013).md — foundational Fernandez-lab (UConn) trial, most-cited (141) in this group; improved HDL/insulin sensitivity with whole eggs. 7. S-64 - Eggs plus spinach in a plant-based diet, metabolic syndrome (Thomas 2022).md — later trial from the same lab/group, independent cohort, again favorable HDL/weight signal.

Eggs within a plant-based diet, at-risk-for-T2D, broader outcome panel 8. S-61 - Eggs in plant-based diets, cardiometabolic risk in adults at risk of T2D (Njike 2021).md — adds endothelial function (FMD) to the usual lipid/glycemic panel; null/favorable for eggs.

Independent (non-Western, non-industry-funded) replication 9. S-51 - Selenium-enriched vs zeaxanthin-enriched eggs in T2D, China (Niu 2026).md — Chinese, government-funded T2D RCT reaching the same null-to-beneficial glycemic/lipid conclusion; useful check on the motivatedness hazard since it is not egg-industry money.

The anti-egg counterweight 10. S-57 - Substituting eggs for high-carbohydrate breakfast foods, at-risk-for-T2D (Maki 2020).md — the one source in this slice with an adverse-leaning signal: LDL-C fell significantly less with eggs than with a higher-carb comparator, despite (and reported by) an egg-industry-funded trial; HOMA-IR and systolic BP were better with eggs in the same trial. The clearest genuinely mixed result found.

search_scope

WebSearch (until the session’s shared WebSearch quota was exhausted partway through — see gaps) for each named anchor (DIABEGG, Ballesteros 2015, Pearce 2011, Blesso 2013, Njike) plus generic queries (“egg RCT type 2 diabetes glycemic lipid”, “egg intervention adverse LDL diabetic”, “diabetic hyper-responders dietary cholesterol egg”). Mined Richard et al. 2017 (Can J Diabetes 41(4):453-463, “Impact of Egg Consumption on Cardiovascular Risk Factors in Individuals with Type 2 Diabetes and at Risk for Developing Diabetes: A Systematic Review of Randomized Nutritional Intervention Studies” — 10 articles/6 original trials, no adverse effect on major CVD risk factors, HDL rose in 4/6 trials) as the main discovery hub; did not find a distinct DIABEGG protocol paper, a “Sparks” egg-glycemic review, or a Cochrane-specific egg-in-T2D review under those names (see gaps). After the WebSearch quota was exhausted, continued via WebFetch directly against PubMed/journal pages and the Semantic Scholar Graph API (api.semanticscholar.org) for citation counts and metadata confirmation.

exclusions

1. Njike VY et al. 2010, Nutrition Journal 9:28 (“Daily egg consumption in hyperlipidemic adults”) — population explicitly excludes diabetes and is defined by hyperlipidemia (TC>240 or LDL>160 or TC/HDL>5.7), not T2D/prediabetes/metabolic syndrome — belongs to slice 4, not this slice. Notable near-miss: it did find an adverse-leaning signal (egg substitute reduced LDL/TC significantly more than whole eggs over 6 weeks, and improved FMD more) — worth slice 4/9 knowing this exists as a hyperlipidemic-population parallel to this slice’s Maki 2020 counterweight.
2. Mesas AE et al. 2022, J Clin Endocrinol Metab 107(3):e963-e972 (EVIDENT II) — cross-sectional/observational FFQ analysis of baseline data nested in an RCT, not an interventional egg comparison; closer to slice 3/9 territory. Found no subgroup (obesity/hypertension/T2D/dyslipidemia) with a worsened lipid response to higher egg intake. Not minted.
3. Blesso et al. 2013, J Clin Lipidol 7(5):463-71 — companion paper to S-43 - Whole egg vs egg substitute in carbohydrate-restricted diet, metabolic syndrome (Blesso 2013).md, same trial/n, reports the same cohort’s broader risk-factor panel (incl. null VCAM-1/ICAM-1). Not separately minted; noted in S-43’s body.
4. Njike et al., diet-quality companion paper (J Am Coll Nutr, 2021/2022) — companion to S-61 - Eggs in plant-based diets, cardiometabolic risk in adults at risk of T2D (Njike 2021).md, same trial. Not separately minted.
5. Thomas/Fernandez, oxidative-stress/inflammation companion (Nutrients 14(12):2548, 2022) — companion to S-64 - Eggs plus spinach in a plant-based diet, metabolic syndrome (Thomas 2022).md, same trial. Not separately minted.
6. Richard et al. 2017 (Can J Diabetes) and any other systematic review/meta-analysis of egg RCTs in T2D — discovery hubs only, never minted, per the primary-only rule.

Slice paragraph

10 sources across ~9 distinct trials (DIABEGG’s two papers share one cohort): T2D/prediabetes RCTs from Australia (DIABEGG x2, Pearce), Mexico (Ballesteros), the US (Pourafshar, Njike, Maki), and China (Niu); plus two metabolic-syndrome-defined whole-egg trials from one US lab (Blesso, Thomas). The picture across this slice is strikingly one-sided toward null-to-beneficial: despite actively searching for an RCT reporting an adverse glycemic effect of eggs in this population, none was found. The only genuine counterweight, Maki 2020, is a partial one — an adverse LDL-C signal (not glycemic) inside an otherwise favorable (HOMA-IR, blood pressure), egg-industry-funded trial. Egg-industry funding is common and often disclosed (Pearce explicitly; Maki explicitly; the Fernandez-lab trials probably, though I could not verify their specific funding statements) — the one trial with disclosed non-industry (Chinese government) funding, Niu 2026, reaches the same conclusion, which is some independent check on the motivatedness hazard, though it is a single data point. I could not verify funding/COI for the DIABEGG papers, Ballesteros, Pourafshar, or Njike despite trying multiple mirrors (AJCN, ScienceDirect, ResearchGate all returned 403); these are recorded as unknown rather than guessed. Citation counts for Pourafshar 2018 and Njike 2021 are also unknown — the Semantic Scholar API began rate-limiting (429) partway through. Independence caveat for step 2/5: S-43 and S-64 come from the same lab/group (Fernandez, UConn) and should probably be treated as correlated on lab-level practices even though they are different cohorts.